Back

Intermittent levosimendan infusions for advanced heart failure: a systematic review and meta-analysis of randomized controlled trials.

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Phenotypic approach in heart failure therapy Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mohamed Abouzid

Poznan University of Medical Sciences, Poznan (Poland)

7 More presentations in this session

Presentation thumbnail
In-hospital initiation of Vericiguat and short-term cardiovascular function improvement in heart failure patients with worsened renal function
Professor J. She (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Effects of Dapagliflozin on myocardial performance in non-diabetic patients with Heart failure with reduced and mid-range ejection fraction (DAPA ECHO trial)
Doctor M. Pastore (Siena, IT) Doctor A. Stefanini (Siena, IT)
Abstract Slides Video
Presentation thumbnail
Comparison of ventricular tachyarrhythmias in HF patients on dapagliflozin versus empagliflozin
Doctor P. Wilson (Dallas, US)
Abstract Slides Video
Presentation thumbnail
Real-world eligibility for GLP1-ra therapy in a cohort of heart failure patients
Doctor A. Villaschi (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Secondary erythrocytosis / polycythemia due to sodium glucose co-transporter 2 inhibitors: a real world heart failure cohort.
Miss M. Pherai (Rotterdam, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Phenotypic approach in heart failure therapy

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Trend of echocardiographic parameters, ventricular-arterial coupling, and biomarkers in advanced heart failure patients undergoing intermittent home-based levosimendan infusion
thumbnail
Congress Presentation
Changes in hemodynamic, strain and myocardial work parameters predict long term mortaility and rehospitalization in acute, decompensated heart failure after levosimendan administration.
thumbnail
Congress Presentation
Single centre 3-year experience in intermittent levosimendan infusion

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources